



# State of the Art Management of Patients with Neuromyelitis Optica

## Reference List

- Cortese R, Carrasco FP, Tur C, et al. Differentiating multiple sclerosis from AQP4-neuromyelitis optica spectrum disorder with MOG-antibody disease with imaging. *Neurology*. 2023;100:e308-e323. doi:[10.1212/WNL.0000000000201465](https://doi.org/10.1212/WNL.0000000000201465)
- Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-Momentum): a double-blind, randomized placebo-controlled phase 2/3 trial. *Lancet Neurol*. 2019;394(10206):1352-1363. doi:[10.1016/S0140-6736\(19\)31817-3](https://doi.org/10.1016/S0140-6736(19)31817-3)
- Giovannelli J, Ciron J, Cohen M, et al. A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica. *Ann Clin Transl Neurol*. 2021;8(10):2025-2037. doi:[10.1002/acn3.51451](https://doi.org/10.1002/acn3.51451)
- Glisson CC. Neuromyelitis optica spectrum disorder (NMOSD): clinical features and diagnosis. UptoDate. Updated: August 30, 2022. Accessed August 30, 2023. <https://www.uptodate.com/contents/neuromyelitis-optica-spectrum-disorder-nmosd-clinical-features-and-diagnosis>
- Gravier-Dumoncaeu A, Ameli R, Rogemond V, et al. Glial fibrillary acidic protein autoimmunity. *Neurology*. 2022;98:e653-e668. doi:[10.1212/WNL.0000000000013087](https://doi.org/10.1212/WNL.0000000000013087)
- Held F, Klein AK, Berthele A. Drug treatment of neuromyelitis optica spectrum disorders: out with the old, in with the new? *ImmunoTargets Ther*. 2021;10:87-101. doi:[10.2147/ITT.S287652](https://doi.org/10.2147/ITT.S287652)
- Huang TL, Wang JK, Chang PY, et al. Neuromyelitis optica spectrum disorder: from basic research to clinical perspectives. *Int J Mol Sci*. 2022;23:7908. doi:[10.3390/ijms23147908](https://doi.org/10.3390/ijms23147908)
- Jarius S, Aktas O, Azyenberg I, et al. on behalf of the Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: diagnosis and differential diagnosis. *J Neurol*. 2023;270:3341-3368. doi:[10.1007/s00415-023-11634-0](https://doi.org/10.1007/s00415-023-11634-0)
- Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. *J Neuroinflammation*. 2012;9:14. <https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094-9-14>
- Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, Kozubski W. The immunology of neuromyelitis optica – current knowledge, clinical implications, controversies and future perspectives. *Int J Mol Sci*. 2016;17(3):273. doi:[10.3390/ijms17030273](https://doi.org/10.3390/ijms17030273)
- Kim HJ, Nakashima I, Viswanathan S, et al. on behalf of the PREVENT Study Group. Eculizumab in Asian patients with anti-aquaporin IgG-positive neuromyelitis optica spectrum disorder: a subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension. *Mult Scler Relat Disord*. 2021;50:102849. doi:[10.1016/j.msard.2021.102849](https://doi.org/10.1016/j.msard.2021.102849)
- Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. *Brain*. 2012;135:1834-1849. doi:[10.1093/brain/aws109](https://doi.org/10.1093/brain/aws109)
- Kleiter I, Gahlen A, Borisow N, et al. Apheresis therapies for NMOSD attacks: A retrospective study of 207 therapeutic interventions. *Neurol Neuroimmunol Neuroinflamm*. 2018;5(6):e504. doi:[10.1212/NXI.0000000000000504](https://doi.org/10.1212/NXI.0000000000000504)



# State of the Art Management of Patients with Neuromyelitis Optica

Kleiter I, Traboulsee A, Palace J, et al. Long-term efficacy of satralizumab in AQP4-IgG-seropositive neuromyelitis optica spectrum disorder from SAKuraSky and SAKuraStar. *Neurol Neuroimmunol Neuroinflamm*. 2023;10:e200071. doi:[10.1212/NXI.0000000000200071](https://doi.org/10.1212/NXI.0000000000200071)

Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M. Comparison of relapse and treatment failure rates among patients with neuromyelitis optica. *JAMA Neurol*. 2014;71(3):324-330. doi:[10.1001/jamaneuro.2013.5699](https://doi.org/10.1001/jamaneuro.2013.5699)

Min JH, Capobianco M, Welsh C, et al. Understanding treatment decisions in neuromyelitis optica spectrum disorder: a global clinical record review with patient interviews. *Neurol Ther*. 2023;12:619-633. doi:[10.1007/s40120-022-00431-y](https://doi.org/10.1007/s40120-022-00431-y)

New analysis of MRI findings show UPLIZNA® (inebilizumab-cdon) reduced the formation of asymptomatic optic nerve lesions in people with neuromyelitis optica spectrum disorder (NMOSD). News Release. Horizon Therapeutics. Published March 14, 2023. Accessed August 23, 2023. <https://ir.horizontherapeutics.com/news-releases/news-release-details/new-analysis-mri-findings-show-upliznar-inebilizumab-cdon>

Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder. *N Engl J Med*. 2019;381:614-625. doi:[10.1056/NEJMoa1900866](https://doi.org/10.1056/NEJMoa1900866)

Pittock SJ, Fujihara K, Palace J. Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension. *Mult Scler*. 2022;28(3):480-486. doi:[10.1177/13524585211038291](https://doi.org/10.1177/13524585211038291)

Poblete CM, Fernandez PC. Pathophysiological basis of neuromyelitis optica spectrum disorders: what do we know? *Rev Chil Neuro-psiquiatr*. 2020. <https://www.journalofneuropsychiatry.cl/docs/5/29.pdf>

Rensel M, Zabeti A, Mealy MA, et al. Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ≥4 years in the N-Momentum trial. *Mult Scler*. 2022;28(6):925-932. doi:[10.1177/13524585211047223](https://doi.org/10.1177/13524585211047223)

Smith AD, Moog TM, Burgess KW, McCreary M, Okuda DT. Factors associated with the misdiagnosis of neuromyelitis optica spectrum disorder. *Mult Scler Relat Disord*. 2023;70:104498. doi:[10.1016/j.msard.2023.104498](https://doi.org/10.1016/j.msard.2023.104498)

Traboulsee A, Greenberg BM, Bennett JL, et al. Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomized, double-blind, multicenter, placebo-controlled phase 3 trial. *Lancet Neurol*. 2020;19(5):404-412. doi:[10.1016/S1474-4422\(20\)30078-8](https://doi.org/10.1016/S1474-4422(20)30078-8)

Wildner P, Stasiolek M, Matsiak M. Differential diagnosis of multiple sclerosis and other inflammatory CNS diseases. *Mult Scler Relat Disord*. 2020;37:101452. doi:[10.1016/j.msard.2019.101452](https://doi.org/10.1016/j.msard.2019.101452)

Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. *Neurology*. 2015;85(2):177-189. doi:[10.1212/WNL.0000000000001729](https://doi.org/10.1212/WNL.0000000000001729)

Wingerchuk DM, Fujihara K, Palace J, et al. Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD. *Ann Neurol*. 2021;89:1088-1098. doi:[10.1002/ana.26049](https://doi.org/10.1002/ana.26049)

Wu Y, Zhong L, Geng J. Neuromyelitis optica spectrum disorder: pathogenesis, treatment, and experimental models. *Mult Scler Relat Disord*. 2019;27:412-418. doi:[10.1016/j.msard.2018.12.002](https://doi.org/10.1016/j.msard.2018.12.002)

Yamamura T, Kleiter I, Fujihara K, et al. Trial of satralizumab in neuromyelitis optica spectrum disorder. *N Engl J Med*. 2019;381:2114-2124. doi:[10.1056/NEJMoa1901747](https://doi.org/10.1056/NEJMoa1901747)